Intrinsic properties across drug treatments
| Incubation | IH sag, mV | Holding RMP, mV | Rm, MΩ | Significant time × drug effect on baseline I/O curve compared to baseline ACSF/VEH, 800 ms |
|---|---|---|---|---|
| ACSF | ||||
| Baseline | 10.5 ± 1.2 | −71.4 ± 0.7 | 285.2 ± 34.4 | |
| VEH | 8.0 ± 1.7a | −70.3 ± 0.9 | 249.3 ± 43.8 | |
| ACSF | ||||
| Baseline | 9.8 ± 1.1 | −70.1 ± 0.2 | 223.7 ± 21.0 | No difference, p = 0.9360 |
| CRF | 7.2 ± 1.1a | −69.5 ± 0.4 | 188.3 ± 20.5 | |
| ZD7288 | ||||
| Baseline | 0.6 ± 0.4b | −71.5 ± 0.5 | 340.0 ± 36.4# | No difference, p = 0.5111 |
| CRF | −0.5 ± 0.5b | −70.2 ± 0.7 | 332.0 ± 53.1# | |
| Apamin | ||||
| Baseline | 8.6 ± 1.1 | −73.1 ± 1.1 | 193.0 ± 13.0 | Decrease, p = 0.0004 |
| CRF | 6.9 ± 0.9 | −71.6 ± 0.7 | 180.5 ± 33.2 | |
| Rp-cAMPs | ||||
| Baseline | 5.9 ± 1.3 | −68.7 ± 0.5 | 147.6 ± 22.5 | No difference, p = 0.8730 |
| CRF | 3.9 ± 1.1 | −69.5 ± 0.4 | 126 ± 14.2 | |
| PKI 14–22 | ||||
| Baseline | 8.8 ± 1.2 | −69.4 ± 0.5 | 181.4 ± 14.6 | Increase, p < 0.0001 |
| CRF | 7.3 ± 1.4 | −69.1 ± 0.5 | 190.6 ± 14.4 | |
| Chelrythrine | ||||
| Baseline | 10.3 ± 1.8 | −70.1 ± 0.6 | 233.1 ± 35.8 | No difference, p > 0.9999 |
| CRF | 10.9 ± 2.7 | −68.7 ± 0.7 | 268.0 ± 42.9 | |
| Go 6983 | ||||
| Baseline | 8.5 ± 1.2 | −69.8 ± 0.6 | 261.4 ± 50.2 | No difference, p = 0.2971 |
| CRF | 8.1 ± 1.6 | −68.3 ± 1.0 | 298.3 ± 60.5 | |
↵aSidak's post hoc t test: baseline versus VEH/CRF.
bSidak's post hoc test: drug incubation versus ACSF.